Likes Subject
$MDGL: HEPA is the Cheapest value in NASH space makinezmoney 12/30/22 11:19 AM
$500 will be here soon enough! TechandBio 12/29/22 8:38 PM
Riding free shares 300% profits last week was
Bullish
Bullish
TechandBio 12/25/22 9:54 PM
Moew like $185. Alan Brown 12/23/22 3:52 AM
$MDGL: Largest OI right now is Jan20,2023 $120puts makinezmoney 12/22/22 2:07 PM
$MDGL: WOW ..... 315......... going to $400 ??? makinezmoney 12/22/22 9:54 AM
$MDGL: Killing it now......... OVER 300 !!!!!!!!!!!!
Bullish
Bullish
makinezmoney 12/22/22 9:37 AM
Wait, is this ganna create sell off tomorrow? 4:19 News eddyimano 12/21/22 8:27 PM
Oh, well There are no set rules regarding how eddyimano 12/21/22 6:38 PM
I am sure a lot of traders are eddyimano 12/21/22 6:32 PM
$MDGL: JUst amazing now............ 275 !!!!!!!!!! makinezmoney 12/21/22 10:43 AM
MDGL might be holding well because smart investors eddyimano 12/21/22 12:26 AM
$MDGL has $49.81M DEBT, Book value is only
Bearish
Bearish
BottomBounce 12/19/22 9:21 PM
MDGL > 52-week serial liver biopsy Phase 3 crudeoil24 12/19/22 1:24 PM
$MDGL: Thanks for that......... I hope AADI makinezmoney 12/19/22 11:48 AM
I saw your post sent you a heads up IOUBLOKE1 12/19/22 10:35 AM
$MDGL : Some genius grabbed 3200 Jan2023 $100calls makinezmoney 12/19/22 9:50 AM
Just in case 87 went to 220 IOUBLOKE1 12/19/22 7:25 AM
87 today as well lol. I knew I Brokemillwright 02/11/22 9:01 PM
$87 today roadkilll 02/09/22 2:04 PM
Keeps inching up Glider549 02/03/22 9:26 AM
Iook like earnings or something coming end of Brokemillwright 01/31/22 10:31 AM
Now its getting attention. Glider549 01/31/22 10:18 AM
Share price could care less tho lol Brokemillwright 01/31/22 10:16 AM
Great news today! Glider549 01/31/22 9:05 AM
News in the AM, pre announced today... see Brokemillwright 01/31/22 12:43 AM
Piper Sandler presentation roadkilll 12/07/21 9:27 PM
Madrigal at 52 week lows because it is roadkilll 10/28/21 3:36 PM
I heard there was news today but I RSummers 07/31/20 1:47 AM
BioVie is unbelievably way under-the-radar. It is the Trend-Setter 03/21/19 3:06 PM
BioVie, Inc. (BIVI) Trend-Setter 03/21/19 3:03 PM
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals DMOST 02/18/19 1:36 PM
Here is What Hedge Funds Think About Madrigal DMOST 12/13/18 5:17 AM
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November DMOST 12/08/18 10:30 PM
MDGL has now lost all the gains from DMOST 11/20/18 11:45 AM
Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking DMOST 11/15/18 3:33 AM
Madrigal preparing for late-stage testing of experimental NASH treatment DMOST 11/13/18 9:41 AM
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic DMOST 11/13/18 9:38 AM
Madrigal: 3Q Earnings Snapshot DMOST 11/06/18 9:54 AM
Madrigal Pharmaceuticals Is Advancing Its NASH Pipeline in 2018 DMOST 10/19/18 4:24 PM
Why Analysts See a Massive Upside in Madrigal Stock DMOST 10/03/18 3:43 PM
5 Biotech Stocks to Play the Sector’s Next DMOST 09/27/18 8:31 AM
Is Viking Therapeutics the Best NASH Stock to DMOST 09/20/18 9:12 PM
Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals DMOST 09/19/18 12:13 PM
Viking Therapeutics and Madrigal Pharmaceuticals Are Racing to DMOST 09/19/18 12:12 PM
3 Top Stocks for Investing in Pharma's Next DMOST 09/12/18 10:36 PM
MDGL buy 243.92 stocktrademan 08/21/18 1:23 PM
Is Viking Therapeutics, Inc. a Buy? DMOST 08/20/18 1:37 AM
Madrigal Pharmaceuticals Inc (MDGL) DMOST 08/13/18 11:49 PM
Madrigal (MDGL) Posts Narrower than Expected Loss in Q2 DMOST 08/07/18 10:39 PM
Likes Subject

makinezmoney
12/30/22 11:19 AM
TechandBio
12/29/22 8:38 PM
TechandBio
12/25/22 9:54 PM
Alan Brown
12/23/22 3:52 AM
makinezmoney
12/22/22 9:54 AM
eddyimano
12/21/22 6:32 PM
BottomBounce
12/19/22 9:21 PM
crudeoil24
12/19/22 1:24 PM
makinezmoney
12/19/22 11:48 AM
IOUBLOKE1
12/19/22 10:35 AM
IOUBLOKE1
12/19/22 7:25 AM
Brokemillwright
02/11/22 9:01 PM
roadkilll
02/09/22 2:04 PM
Glider549
02/03/22 9:26 AM
Brokemillwright
01/31/22 10:31 AM
Glider549
01/31/22 10:18 AM
Brokemillwright
01/31/22 10:16 AM
Glider549
01/31/22 9:05 AM
Brokemillwright
01/31/22 12:43 AM
roadkilll
12/07/21 9:27 PM
roadkilll
10/28/21 3:36 PM
RSummers
07/31/20 1:47 AM
Trend-Setter
03/21/19 3:03 PM
DMOST
11/20/18 11:45 AM
DMOST
11/06/18 9:54 AM
stocktrademan
08/21/18 1:23 PM
DMOST
08/20/18 1:37 AM
DMOST
08/13/18 11:49 PM

Madrigal Pharmaceuticals Inc (MDGL)

Followers
16
Posters
33
Posts (Today)
0
Posts (Total)
157
Created
07/25/16
Type
Free
Moderators

 
WEBSITE: http://www.madrigalpharma.com


NEW MADRIGAL/SYNTA CORPORATE PRESENTATION:

http://www.madrigalpharma.com/wp-content/uploads/2016/05/Synta-Madrigal-Corporate-Slide-Deck-2060501.pdf
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease. Madrigal’s lead drug candidate is MGL-3196, a Phase 2 ready orally administered liver-directed thyroid hormone receptor-ß (THR-ß) agonist. In Madrigal’s 14-day multiple dose Phase 1 study in healthy volunteers with mildly elevated LDL cholesterol, MGL-3196 demonstrated safety and excellent tolerability at all doses tested. In the multiple dose study, MGL-3196 demonstrated proof-of-concept for lipid lowering including dose-dependent, highly significant, up to 30% lowering of LDL cholesterol and non-HDL cholesterol, and a strong trend of up to 60% triglyceride lowering. These results suggest that MGL-3196 has a unique lipid lowering profile as compared with other agents and a potential to significantly reduce cholesterol, triglycerides and liver triglycerides. Elevated cholesterol, triglycerides and fatty liver are an underlying cause of many metabolic and cardiovascular diseases, which, themselves, are associated with increased mortality.

In addition, MGL-3196 is a NASH target supported by compelling human biology and genetics. NASH is a serious liver disease found in individuals with fatty liver disease that is associated with hypothyroidism, diabetes, obesity, and dyslipidemia. MGL-3196 Phase 1 human data demonstrate safety and benefit in NASH-related dyslipidemia, and data from MGL-3196 treated NASH animal models support efficacy in NASH at doses relevant to humans.
 
Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post